KDCA discusses COVID-19 vaccine supply and future infectious disease response with Pfizer

The Korea Disease Control and Prevention Agency (KDCA) announced on the 8th that it held a meeting with the U.S. pharmaceutical company Pfizer to discuss the smooth supply of COVID-19 vaccines and treatments, as well as cooperation plans for future infectious disease responses.

The meeting, held on the 7th at a restaurant in Jung-gu, Seoul, was attended by KDCA Commissioner Ji Young-mi, Pfizer’s Aileen Twisler, Vice President and Global Head of Advanced Markets Comirnaty/mRNA Strategy, and Oh Dong-wook, President of Pfizer Korea. They discussed ▲ the smooth supply of COVID-19 vaccines and treatments ▲ COVID-19 vaccine development and supply plans ▲ and mid- to long-term cooperation plans for future pandemic responses.

During the meeting, KDCA and Pfizer also exchanged views on ways to increase COVID-19 vaccination rates, Pfizer’s vaccine supply plans, and vaccination trends in major advanced countries. Aileen Twisler, Pfizer’s Vice President, emphasized, “Prevention and treatment through COVID-19 vaccination for high-risk groups such as the elderly remain important, so Pfizer plans to reliably supply high-quality vaccines and treatments.”

KDCA Commissioner Ji Young-mi said, “We appreciate Pfizer’s cooperation in smoothly supplying vaccines and treatments since the early stages of the COVID-19 outbreak and providing clinical vaccines to domestic companies developing follow-up vaccines,” adding, “We will continue to cooperate and discuss various measures for future infectious disease responses.”